Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system

摘要

Background: The acceptability of and retention on extended-release naltrexone (XR-NTX), an FDA-approved medication for the treatment of alcohol and opioid use disorders, among persons living with HIV disease (PLH) under criminal justice setting (CJS) supervision has not been evaluated to date.